Short-form video platforms like TikTok, Instagram Reels, and YouTube Shorts contribute to poorer cognitive and mental health, or “brain rot”, among viewers, per an analysis by Griffith University researchers. Research has previously linked social media use to mental health risks, especially for adolescents and young adults, but the rapid spread of short-form video adds a newer and increasingly common point of exposure.

Among patients newly prescribed GLP-1s for obesity, 90% either never start therapy or discontinue within a year. Novo and Lilly are using their direct-to-consumer online pharmacies to improve adherence, giving them clearer insight into why patients don’t fill or refill prescriptions to offer targeted support. Beyond that, drugmakers should work with their telehealth partners and pharmacies to give patients resources on managing side effects, navigating insurance issues, and understanding why maintenance dosing remains important after achieving some weight loss.

The FDA is introducing agentic AI to help its drug reviewers, investigators, and scientists carry out more complex tasks and develop AI-driven workflows. Its move into agentic AI signals that AI-driven review is becoming a regulatory norm.

Health insurance outranks all other factors when people consider their next career move, according to a recent survey from Talker Research and Oscar Health. While employers are unlikely to take on more healthcare costs soon due to their own financial strain, they must prioritize worker retention and use open enrollment for transparent communication on cost increases and plan adjustments

The UK will increase the price it pays for new medicines in exchange for evading tariffs on pharmaceutical exports to the US, under a trade agreement reached between the two governments on Monday. The deal is further affirmation that Trump will use tariff threats as a bargaining tool to advance what he views as larger measures against the pharma industry: increasing domestic drug production, reducing the cash-pay prices of some expensive medicines, and bringing US drug costs closer in line with those in other affluent countries.

Eli Lilly is dropping the price of its weight loss drug Zepbound for cash-pay customers, following rival Novo Nordisk’s price cut less than two weeks ago. Lilly and Novo’s newly lowered D2C prices will help some cash-pay consumers, but the affordability gap is a major barrier to broader adoption.

Two-thirds (65%) of pharma marketers are wary of AI use for creating regulatory filings, according to a new Klick Health and Momentum Events survey. While AI-assisted review is likely to become a standard part of regulatory workflows for both industry submissions and agency evaluations, human oversight will remain important.

Novo Nordisk has applied for approval of a higher-dose version of its weight loss drug Wegovy using a special FDA review pathway for a faster decision. Novo’s move to introduce a higher-dose Wegovy shifts competitive expectations in the weight loss category in terms of speed and effectiveness, with over 20% weight loss becoming the new benchmark for success.

OpenAI has refuted legal claims that ChatGPT is at fault for a teenager’s recent suicide. Scrutiny of AI tools being used for emotional and therapeutic support will only intensify. Both general-purpose platforms and specialized healthcare AI tools should proactively take action to impose age restrictions, automatically end sessions at the first sign of emotional distress, and clearly direct users to mental health resources when appropriate.

The Trump administration announced lower Medicare prices for 15 prescription drugs via the Medicare drug price negotiation program. The new prices will take effect starting January 1, 2027. The biggest hit will fall on pharma companies with drugs selected in both rounds of Medicare negotiations. Revenue impacts will vary depending on each product’s time on the market and how far the negotiated price falls below prior net sales after rebates and discounts. For the government, savings on these drugs will be significant, but broader program savings won’t materialize until far more than 25 drugs see price cuts.

Novo Nordisk’s GLP-1 drug semaglutide failed to slow the progression of Alzheimer’s disease in new study results, dashing hopes that GLP-1s might one day be approved to treat the condition. Novo’s Alzheimer’s results underscore the boundary of how far GLP-1s can stretch beyond metabolic diseases.

Spending significantly less time with social media can reduce young people’s symptoms of anxiety, depression, and insomnia, according to a study recently published in JAMA Open Network. As with questions about nutrition, substance use, and other issues that affect a person’s health, clinicians should ask patients during appointments about their social media use and use the responses to deliver guidance on the risks of excessive time online. Healthcare marketers at provider organizations can also create resources for doctors to share with patients showing how too much social media and phone time can harm overall health.

43% of primary care physicians in the US report feeling burned out, the highest share among 10 countries surveyed by the Commonwealth Fund. As primary care doctors and nurses continue to face heavy administrative burdens and burnout, even as new loan limits make medical education less affordable, the clinician shortage will likely worsen.

Eli Lilly became the first healthcare or pharma company to reach a $1 trillion valuation. Pharma’s entry into “the trillion-dollar club” is largely driven by success in the obesity treatment category that’s poised to reshape consumer health and wellness. However, Lilly’s particular rapid growth signals that while first-mover advantage in a high-demand disease area matters, it doesn’t guarantee staying on top. Pharma manufacturers can make up for not being first by committing to innovative drug development that drives more efficacious products, pursuing new clinical indications, and correctly anticipating market developments that may impact supply and demand.

Starting next year, Novo Nordisk and Eli Lilly will sell their weight loss shots directly to employers, cutting out pharmacy benefit managers, per Bloomberg. This move further signals drugmakers’ push into direct sales, both to consumers and employers. More businesses will likely cover obesity drugs for their workers if they can achieve greater cost control of their offered benefits. And pharma supply chain middlemen could feel mounting pressure to shift further away from the prescription drug rebate model that so many in the industry decry.

Lab testing company Function Health raised a $298 million oversubscribed Series B funding round, bringing the company’s valuation to $2.5 billion. Consumer adoption of cash-pay wellness services is surging, though offerings exceeding $1,000 all-in may see constrained demand. Companies entering D2C lab testing should avoid overpromising the value of testing hundreds of biomarkers, ground their claims in solid science, and be transparent about pricing—including add-on costs.

Digital health tech funding continues to rebound in 2025, bolstered by AI deals. Funding reached $3.9 billion in Q3, already surpassing last year’s total, per PitchBook. AI is driving a new wave of digital health investment, and both healthcare systems and providers will feel pressure to adopt AI-assisted tool, not just experiment with them.

House Democrats introduced a new healthcare bill on Thursday aimed at expanding prescription drug price negotiations and extending Medicare benefits to consumers covered by private insurance. The proposal is unlikely to advance out of the House, but it adds fuel to the ongoing debate over drug pricing, and increases the pressure on pharma companies.

Abbott is spending $21 billion to buy cancer testing company Exact Sciences, known for its Cologuard colorectal cancer at-home test in a box. Abbott’s purchase of Exact highlights the move toward consumer-friendly at-home cancer screenings.

CVS Health’s Aetna is adding conversational generative AI (genAI) to its insurance website and mobile app. Aetna’s move highlights how insurers can use genAI to become more attractive to employer benefit packages.